The U.S. National Academy of Medicine’s Healthy Longevity Global Grand Challenge has awarded a grant to develop Entopsis’ OpsisDx(TM) platform for detecting Parkinson’s disease using skin swabs or urine. This effort is driven by Entopsis’ scientific and clinical collaborators at Singapore’s Temasek Life Sciences Laboratory (TLL) and National Neuroscience Institute (NNI).

Read more about it here:

https://www.einnews.com/pr_news/529273833/national-academy-of-medicine-selects-opsisdx-for-co-development-of-a-urine-based-diagnostic-for-parkinson-s-disease

Non-invasive OpsisDx Diagnostic Test Awarded US Academy Research Grant

Our team’s passion is to innovate and create powerful, unheard-of solutions to the world’s problems. We pride ourselves on our creativity and desire to make a meaningful difference, both socially and scientifically.

However, we can only achieve our global goals with the right partners that share our mission. Today’s press release (see below) highlights one such partner, Madison Core Labs.

Link to Press Release

Madison Core Laboratories Initiates New Innovation Effort to Better Serve Clients

August 13, 2020 09:05 AM Eastern Daylight Time

HUNTSVILLE, Ala.–(BUSINESS WIRE)–Read more

Genetics Institute of America (GIA) received IRB approval to expand its Prostate Cancer Study (GH215) utilizing OpsisDx to include: Breast, Ovarian and Lung Cancers. OpsisDx will be used to develop accurate, non-invasive tests for the early detection of these 3 additional cancers.

GIA, empowered by OpsisDx, will be able to screen people for prostate, breast, ovarian, and / or lung cancers once these 4 studies are completed. These tests are expected to detect tumors earlier than liquid biopsies and thereby outperform GRAIL (valued at over $4 billion).

The Entopsis team will continue to support GIA’s efforts of bring impactful tools

Is viral RNA extraction necessary for amplifying genes from coronaviruses, like SARS-CoV-2?

NOT ANY MORE!

PCRopsis Reagent RVD allows you to perform direct RT-qPCR from nasopharyngeal / oropharyngeal samples transported in BD Universal Viral Transport media or Copan ESwab.

Simple Protocol:

  1. Mix sample 1:1 with Reagent RVD
  2. Heat to 95C for 10 minutes
  3. DONE… use ~5 uL into your RT-qPCR mix (can use 5 uL into a total 20 uL reaction)

Key Features:

  • Reagent RVD is an alternative to RNA extraction
  • Offers comparable RT-qPCR results to RNA extraction procedures for many applications in 10 MINUTES
  • Cost a fraction of traditional RNA extraction procedures, with fewer steps
  • Compatible with leading

“The U.S. Food and Drug Administration (FDA) reminds laboratory staff to use transport media (the liquid that maintains a specimen sample while it is transported to a laboratory) that are compatible with the SARS-CoV-2 testing platforms and the processes used in their laboratory to process samples collected from people who are being tested for SARS-CoV-2. There is a risk of exposure to harmful cyanide gas, a by-product of a reaction between guanidine thiocyanate or similar chemicals and bleach (sodium hypochlorite), when certain transport media are used with an incompatible testing platform or laboratory process. Guanidine thiocyanate may be referred to

‘Why OpsisDx?’ is a blog series written by people part of the Entopsis-verse and offers insights into potential OpsisDxTM addressable medical conditions.

In modern times, cardiovascular disease (CVD) has become just as worrisome as epidemics in the early stages of medicine. Currently, CVD accounts for around 50% of deaths in richer countries, making it an important area for research, therapeutics and diagnostics. 

Known cardiovascular risk factors include lipid disorders, high blood pressure, smoking, obesity, diabetes and sedentariness (1). Although these risk factors are broad and encompass many areas, the influence of the microbiome, complex stress responses and psychiatric disorders also

‘Why OpsisDx?’ is a blog series written by people part of the Entopsis-verse and offers insights into potential OpsisDxTM addressable medical conditions.

Irritable bowel syndrome (IBS) is one of the most commonly encountered conditions in primary care and gastroenterology clinics. This condition has a prevalence of around 10-15% worldwide and, while this condition is not lethal, patients experience a sharp decline in their quality of life because of how debilitating this condition can be (2). Hallmark symptoms of IBS include changes in bowel habits, abdominal bloating and chronic abdominal discomfort/pain. (1). The etiology of this condition is not fully understood

1) CLIA Lab Director (Ph.D. with LDT development experience)
Location: Orlando, FL, USA

2) CLIA Medical Technologist (management experience needed)
Location: Orlando, FL, USA

3) Computer Scientist – Machine Learning
Location: Singapore, Singapore

4) Online Sales / Marketing
Location: global (all work is online)

5) Personal / Business Assistant to CEO (…a jack of all trades)
Location: Miami, FL, USA

6) Content Writer (little work experience necessary, but must be a daring writer)
Location: Miami, FL, USA

info@entopsis.com

Our team of multi-disciplinary scientists and engineers have once again improved on the NuTec Slide. This was only made possible by building on past insights and proprietary know-how. The latest version of NuTec Slides show improved reproducibility and sample discernment, while being able to handle a wider range of sample intensities. The Gen 5 NuTec Slide will be used for commercial applications in the U.S.

‘Why OpsisDx?’ is a blog series written by people part of the Entopsis-verse and offers insights into potential OpsisDxTM addressable medical conditions.

Cancer is probably one of the most apprehended conditions in the modern world. Raising to the spotlight in the 20th century and becoming increasingly prevalent while also acquiring higher incidence rates, it is no surprise why this condition has spiked scientists’ interest as well as fueled funding on diagnostics and therapeutics (1). As of 2018, there were 18mil new cases of cancer worldwide, and, around 430K deaths caused by cancer in the pancreas alone (2). 

As illustrated by